Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Blood Transfusion


Published on

  • good
    Are you sure you want to  Yes  No
    Your message goes here
  • Objectives of BLT

    1. To increase circulating blood volume after surgery, trauma, or hemorrhage
    2. To increase the number of RBCs and to maintain hemoglobin levels in clients with severe anemia
    3. To provide selected cellular components as replacements therapy (e.g. clotting factors, platelets, albumin)

    Found this great lecture for Blood Transfusion.
    Are you sure you want to  Yes  No
    Your message goes here

Blood Transfusion

  1. 1. Blood transfusion พญ . เพชรรัตน์ วิสุทธิเมธีกร พ . บ ., ป . ชั้นสูงสาขาวิสัญญีวิทยา , วว . ( วิสัญญี ) ภาควิชาวิสัญญีวิทยา วิทยาลัยแพทยศาสตร์กรุงเทพมหานคร และวชิรพยาบาล
  2. 2. Topic modules <ul><li>Blood blank practices </li></ul><ul><li>Indication to blood transfusion </li></ul><ul><li>Complication </li></ul><ul><li>Alternative strategies for management of blood loss during surgery </li></ul>
  3. 3. Blood blank practices <ul><li>Human red cell membrane : least 300 different antigen </li></ul><ul><li>fortunately, only the ABO and the Rh systems are important in the majority of blood transfusion </li></ul><ul><li>History </li></ul><ul><li>Hct. </li></ul><ul><li>Infection : Hepatitis B,C syphillis HIV-1,2 HTLV-I,II </li></ul>
  4. 4. <ul><li>#Crossmatching (50 min) </li></ul><ul><li>Confirms ABO and Rh typing </li></ul><ul><li>Detects antibodies to the other blood group systems </li></ul><ul><li>Detects antibodies in low titers or those that do not agglutinate easily </li></ul>Blood blank practices
  5. 5. Blood blank practices # Antibody screen : Indirect Coombs test (45 mins) the subject serum + red cells ( antigenic composition) ----- red cell agglutination # Type&screen # Emergency transfusion
  6. 6. <ul><ul><li>T&S -determines ABO and Rh status and the presence of most commonly encountered antibodies – risk of adverse rxn is 1:1000 </li></ul></ul><ul><ul><li>-takes about 5 mins </li></ul></ul><ul><ul><li>T&C -determines ABO and Rh status as well as adverse rxn to even low incidence antigens – risk of rxn is 1:10,000 </li></ul></ul><ul><ul><li>-takes about 45 mins </li></ul></ul>Type and screen vs Type and crossmatch
  7. 7. Type and screen vs Type and crossmatch <ul><li>T&S: </li></ul><ul><li>Type O red cells are mixed with pt serum Antibody screen </li></ul><ul><li>T&C </li></ul><ul><li>Type O red cells are mixed with pt serum Antibody screen </li></ul><ul><ul><li>Donor red cells are then mixed with the pt’s serum to determine possible incompatibility </li></ul></ul>:
  8. 8. Blood blank practices All units – RBC @ PRC 1unit (250 ml Hct.70%) --platelet@ 1 unit (50-70 ml, stored at 20-24c for 5 days) --plasma @ FFP --cryoprecipitate @ high conc. Of factor VII, fibrinogen
  9. 9. Intraoperative transfusion practices <ul><li>PRC </li></ul><ul><li>Ideal for patients requiring red cells but not volume replacement Only one – Increase O 2 carrying capacity </li></ul><ul><li>AGE BLOOD VOLUME </li></ul><ul><li>Neonates </li></ul><ul><li>Premature 95 ml/kg </li></ul><ul><li>Full-term 85 ml/kg </li></ul><ul><li>Infants 80 ml/kg </li></ul><ul><li>Adults </li></ul><ul><li>Men 75 ml/kg </li></ul><ul><li>Women 65 ml/kg </li></ul><ul><li>Allowable blood loss = EBV*( Hct ตั้งต้น – Hct ที่ยอมรับได้ )/ Hct เฉลี่ย </li></ul><ul><li>Hct. 30% not magic number </li></ul><ul><li>Jehovah” s witness </li></ul>
  10. 10. Practice guideline $$ case series : reports of Jehovah witness; some may tolerate very low Hb< 6-8 g/dl in the perioperative period without an incresae in mortality
  11. 11. Practice guideline $$ In healthy, normovolemic individual, tissue oxygenation is maintained and anemia tolerated at Hct as low as 18-25%(Hb 6-8gm%) $$ RBC transfusion is rarely indicated when Hb> 10 g/dl and is almost always indicated when Hb< 6 g/dl American Society Anesthesiologist : 1996
  12. 12. คุณหมอขาหนูหน้าซีดแล้วต้องให้เลือดหนูหรือเปล่าคะ
  13. 13. Intraoperative transfusion practices <ul><li>2. FFP ( initial therapeutic dose : 10-15 ml/kg ) </li></ul><ul><li>isolated factor deficiencies </li></ul><ul><li>reverse warfarin therapy </li></ul><ul><li>correction of coagulopathy associated with liver disease </li></ul><ul><li>used in patients who are received massive blood transfusion with microvascular bleeding </li></ul><ul><li>Complications (PATCH) Platelets – dec,Potassium – inc., ARDS, Acidosis,Temp dec., Citrate intoxication, Hepatiti </li></ul><ul><li>>1 BV/ 24 HR> 50 % BV within 3 hrs > 150 ml/min </li></ul><ul><li>antithrombin III deficiency </li></ul><ul><li>TTP ( Thrombotic thrombocytopenic purpura ) </li></ul><ul><li>Do not use for volume </li></ul>
  14. 14. Intraoperative transfusion practices 3. PLATELETS **thrombocytopenia or dysfunction platelets in the presence bleeding * prophylactic : plt.counts below 10,000-20,000 * prophylactic preoperative : plt.counts below 50,000 *Microvascular bleeding in surgical patient with platelets < 50,000 *Neuro/ ocular surgery > 75,000
  15. 15. Intraoperative transfusion practices 3. PLATELETS <ul><li>*Massive transfusion with microvascular bleeding with platelets < 100,000 </li></ul><ul><ul><li>2 BVs = 50,000 </li></ul></ul><ul><li>*Qualitative dysfunction with microvascular bleeding (may be > 100,000) </li></ul>
  16. 16. Intraoperative transfusion practices 3. PLATELETS 50 ml: 0.5- 0.6 x 10 9 platelets (some RBC’s and WBC’s) Single donor apheresis OR Random donor (x 6)
  17. 17. Intraoperative transfusion practices <ul><li>4. CRYOPRECIPITATE </li></ul><ul><li>10 ml: fibrinogen (150-250 mg), </li></ul><ul><li>VIII (80-145 U), </li></ul><ul><li>fibronectin, XIII </li></ul><ul><li>1U/ 10kg  fibrinogen 50 mg/dL (usually a 6- pack) </li></ul><ul><li>Hypofibrinogenemia (congenital or acquired) </li></ul><ul><li>Microvascular bleeding with massive BT (fibrinogen < 80-100mg/dL) </li></ul><ul><ul><li>2 BVs = < 100 mg/dL </li></ul></ul><ul><li>Bleeding patients with vWD (or unresponsive to DDAVP) </li></ul>
  18. 18. Alternative strategies for management of blood loss during surgery <ul><li>Autologous transfusion </li></ul><ul><li>Blood salvage & refusion </li></ul><ul><li>Normovolemic hemodilution </li></ul>
  19. 20. “ Blood is still the best possible thing to have in our veins” - Woody Allen Blood transfusion is a lot like marriage. It should not be entered upon lightly, unadvisedly or wantonly, or more often than is absolutely necessary” - Beal
  20. 21. คุณหมอขาตัวหนูแดงทั้งตัวแล้ว แล้วคุณหมอเป็นไงบ้าง หัวบวมหรือยังคะ
  21. 22. TRANSFUSION REACTIONS <ul><li>is any unfavorable transfusion-related event occurring in a patient during or after transfusion of blood components </li></ul>
  22. 23. TRANSFUSION REACTIONS <ul><li>@RBC’s ! </li></ul><ul><li>Nonhemolytic 1-5 % transfusions </li></ul><ul><li>Causes - Physical or chemical destruction of </li></ul><ul><ul><ul><li>blood: freezing, heating, hemolytic drug </li></ul></ul></ul><ul><ul><ul><li>-solution added to blood </li></ul></ul></ul><ul><ul><ul><li>-Bacterial contamination </li></ul></ul></ul><ul><li>: fever, chills, urticaria </li></ul><ul><ul><li>Slow transfusion, diphenhydramine , antipyretic for fever </li></ul></ul><ul><li>Hemolytic </li></ul><ul><ul><li>Immediate : ABO incompatibility (1/ 12-33,000) with fatality (1/ 500-800,000) </li></ul></ul><ul><ul><li>Majority are group O patients receiving type A, B or AB blood </li></ul></ul><ul><ul><li>Complement activation, RBC lysis, free Hb (+ direct Coombs Ab test) </li></ul></ul>
  23. 24. Acute Hemolytic Transfusion Reaction Ab ( in recipient serum ) + Ag ( on RBC donor ) - Neuroendocrine responses -Complement Activation -Coagulation Activation - Cytokines Effects Acute hemolytic transfusion reaction Pathophysiology
  24. 25. Acute Hemolytic Transfusion Reactions <ul><li>Acute onset within minutes or 1-2 hours </li></ul><ul><li>after transfuse incompatible blood </li></ul><ul><li>Most common cause is ABO-incompatible </li></ul><ul><li>transfusion </li></ul>
  25. 26. Signs and Symptoms of AHTR <ul><li>Chills , fever </li></ul><ul><li>Facial flushing </li></ul><ul><li>Hypotension </li></ul><ul><li>Renal failure </li></ul><ul><li>DIC </li></ul><ul><li>Chest pain </li></ul><ul><li>Dyspnea </li></ul><ul><li>Generalized bleeding </li></ul><ul><li>Hemoglobinemia </li></ul><ul><li>Hemoglobinuria </li></ul><ul><li>Shock </li></ul><ul><li>Nausea </li></ul><ul><li>Vomitting </li></ul><ul><li>Back pain </li></ul><ul><li>Pain along infusion vein </li></ul>
  26. 27. <ul><ul><li>Anesthesia: hypotension, urticaria, abnormal bleeding </li></ul></ul><ul><ul><li>Stop infusion, blood and urine to blood bank, coagulation screen (urine/plasma Hb, haptoglobin) </li></ul></ul><ul><ul><li>Fluid therapy and osmotic diuresis </li></ul></ul><ul><ul><li>Alkalinization of urine (increase solubility of Hb degradation products) </li></ul></ul><ul><ul><li>Correct bleeding, Rx. DIC </li></ul></ul>
  27. 28. Laboratory investigation for AHTR <ul><li>sample from blood bag Repeat ABO, Rh, Ab screening </li></ul><ul><li>Patient sample </li></ul><ul><li>Pre Tx sample Repeat ABO, Rh, Ab screening </li></ul><ul><li>Post Tx sample Repeat ABO, Rh, Ab screening, DAT, </li></ul><ul><li>CBC, UA, Bilirubin, BUN, Cr, </li></ul><ul><li>Coagulation screening </li></ul><ul><li>Repeat compatibility test </li></ul><ul><li>- Pre Tx sample & Donor unit </li></ul><ul><li>- Post Tx sample & Donor unit </li></ul>
  28. 29. <ul><ul><li>Delayed : (extravascular immune)1/ 5-10,000 </li></ul></ul><ul><ul><li>Hemolysis 1-2 weeks after transfusion (reappearance of Ab against donor Ag from previous exposure) </li></ul></ul><ul><ul><li>Fever, anemia, jaundice </li></ul></ul><ul><ul><li>Alloimmunization </li></ul></ul><ul><ul><li>Recipient produces Ab’s against RBC membrane Ag </li></ul></ul><ul><ul><li>Related to future delayed hemolytic reactions and difficulty crossmatching </li></ul></ul>
  29. 30. <ul><li>@WBC’s! </li></ul><ul><li>Europe: All products leukodepleted </li></ul><ul><li>USA: Initial FDA recommendation now reversed pending objective data (NOT  length of stay for  expense) </li></ul><ul><li>Febrile reactions </li></ul><ul><ul><li>Recipient Ab reacts with donor Ag, stimulates pyrogens (1-2 % transfusions) </li></ul></ul><ul><ul><li>20 - 30% of platelet transfusions </li></ul></ul><ul><ul><li>Slow transfusion, antipyretic, meperidine for shivering </li></ul></ul>
  30. 31. <ul><li>TRALI ( Transfusion related acute lung injury) </li></ul><ul><ul><li>Donor Ab reacts with recipient Ag (1/ 10,000) </li></ul></ul><ul><ul><li>noncardiogenic pulmonary edema </li></ul></ul><ul><ul><li>Supportive therapy </li></ul></ul>
  31. 32. Transfusion-related Acute Lung Injury (TRALI) <ul><li>Pathophysiology </li></ul><ul><li>Leukocyte Ab in donor react with pt. leukocytes </li></ul><ul><li>Activate complements </li></ul><ul><li>Adherence of granulocytes to pulmonary endothelium with release of proteolytic enz.& toxic O 2 metabolites </li></ul><ul><li>Endothelial damage </li></ul><ul><li>Interstitial edema and fluid in alveoli </li></ul>
  32. 33. Transfusion-related Acute Lung Injury (TRALI) <ul><li>Acute and severe type of transfusion reaction </li></ul><ul><li>Symptoms and signs </li></ul><ul><li>Fever </li></ul><ul><li>Hypotension </li></ul><ul><li>Tachypnea </li></ul><ul><li>Dyspnea </li></ul><ul><li>Diffuse pulmonary infiltration on X-rays </li></ul><ul><li>Clinical of noncardiogenic pumonary edema </li></ul>
  33. 34. Transfusion-related Acute Lung Injury (TRALI) <ul><li>Therapy and Prevention </li></ul><ul><li>Adequate respiratory and hemodynamic supportive treatment </li></ul><ul><li>If TRALI is caused by pt. Ab  use LPB </li></ul><ul><li>If TRALI is caused by donor Ab  no special blood components </li></ul>
  34. 35. <ul><li>Transfusion-associated Graft-versus-Host Disease ( TA-GVHD) </li></ul><ul><ul><li>Rare: immunocompromised patients </li></ul></ul><ul><ul><li>Suggestion that more common with designated donors </li></ul></ul><ul><ul><li>BMT, LBW neonates, Hodgkin's disease, exchange Tx in neonates </li></ul></ul>
  35. 36. Transfusion-associated Graft-versus-Host Disease ( TA-GVHD) <ul><li>Pathophysiology </li></ul><ul><li>Infusion of Immunocompetent Cells </li></ul><ul><li>(Lymphocyte) </li></ul><ul><li>Patient at risk </li></ul><ul><li>proliferation of donor T lymphocytes </li></ul><ul><li>attack against patient tissue </li></ul>
  36. 37. Graft-versus-Host Reaction <ul><li>Signs & Symptoms </li></ul><ul><li>Onset ~ 3 to 30 days after transfusion </li></ul><ul><li>Clinical significant – pancytopenia </li></ul><ul><li>Other effects include fever, liver enzyme, </li></ul><ul><li>copious watery diarrhea, </li></ul><ul><li>erythematous skin erythroderma </li></ul><ul><li>and desquamation </li></ul>
  37. 38. <ul><li>@Platelets! </li></ul><ul><li>Alloimmunization </li></ul><ul><ul><li>50 % of repeated platelet transfusions </li></ul></ul><ul><ul><li>Ab-dependent elimination of platelets with lack of response </li></ul></ul><ul><ul><li>Use single donor apheresis </li></ul></ul><ul><ul><li>Signs & Symptoms </li></ul></ul><ul><ul><ul><li>mild  slight fever and Hb </li></ul></ul></ul><ul><ul><ul><li>severe  platelet refractoriness with bleeding </li></ul></ul></ul><ul><li>Post-transfusion purpura </li></ul><ul><ul><li>Recipient Ab leads to sudden destruction of platelets 1-2 weeks after transfusion (sudden onset) </li></ul></ul><ul><ul><li>Rare complication </li></ul></ul>
  38. 39. <ul><li>Immunomodulatory effects of transfusion </li></ul><ul><li>Wound infection: circumstantial evidence (? leukocyte filters for immunocompromised) </li></ul><ul><li>Beneficial effects on renal graft survival (now < NB with CyA) </li></ul><ul><ul><li>97: 9% graft survival advantage after 5 years </li></ul></ul><ul><li>Nonspecific overload of RES </li></ul><ul><ul><li> lymphocytes, APCs </li></ul></ul><ul><ul><li>Modification T helper/suppressor ratio </li></ul></ul><ul><ul><li>Allogeneic lymphocytes may circulate for years after transfusion </li></ul></ul>
  39. 40. <ul><li>Cancer recurrence (mostly retrospective ) </li></ul><ul><ul><li>Colon: 90 % studies suggest increased recurrence </li></ul></ul><ul><ul><li>Breast: 70 % studies </li></ul></ul><ul><ul><li>Head and neck: 75 % studies </li></ul></ul><ul><li>“ Allogeneic blood products increase cancer recurrence after potentially curative surgical resection” - Landers </li></ul><ul><li>Evidence circumstantial NOT causal </li></ul>
  40. 41. INFECTIOUS COMPLICATIONS <ul><li>I. Viral (Hepatitis 88% of per unit viral risk) </li></ul><ul><li>Hepatitis B </li></ul><ul><li>Risk 1/ 200,000 due to HBsAg, antiHBc screening (7-17 % of PTH) </li></ul><ul><li>Per unit risk 1/63-66,000 </li></ul><ul><li>0.002% residual HBV remains in ‘negative’ donors (window 2-16 weeks) </li></ul><ul><li>Anti-HBc testing retained as surrogate marker for HIV </li></ul>
  41. 42. <ul><li>NANB and Hepatitis C </li></ul><ul><li>Risk now 1/ 103,000 (NEJM 96) with 2nd/ 1/ 125,000 with 3rd generation HCV Ab/ HVC RNA tests </li></ul><ul><li>Window 4 weeks </li></ul><ul><li>70 % patients become chronic carriers, 10-20 % develop cirrhosis </li></ul>
  42. 43. <ul><li>HIV </li></ul><ul><li>Current risk 1/ 450- 660,000 (95) </li></ul><ul><li>With current screening (Abs to HIV I, II and p24 Ag), window 6-8 weeks (third generation ELISA tests in Europe) </li></ul><ul><li> sero -ve window to < 16 days </li></ul>
  43. 44. <ul><li>HTLV I, II </li></ul><ul><li>Only in cellular components (not FFP, cryo) </li></ul><ul><li>Risk 1/ 641,000 (window period unknown) </li></ul><ul><li>Screening for antibody I may not pick up II </li></ul><ul><li>CJD (and variant CJD) </li></ul>
  44. 45. <ul><li>CMV </li></ul><ul><li>Cellular components only </li></ul><ul><li>Problem in immunocompromised, although 80 % adults have serum Ab </li></ul><ul><li>WBC filtration decreases risk of transmission </li></ul><ul><li>CMV -ve blood: </li></ul><ul><ul><li>CMV -ve pregnant patients, LBW neonates, CMV -ve transplant recipient, </li></ul></ul><ul><ul><li>CMV-ve/ HIV +ve </li></ul></ul>
  45. 46. <ul><li>II. Bacterial </li></ul><ul><li>Contamination unlikely in products stored for > 72 hours at 1-6 0 C </li></ul><ul><li>gram –ve, gram +ve bacteria </li></ul><ul><li>most frequent – Yersinia enterocolitica </li></ul><ul><li>Produced endotoxin </li></ul><ul><li>Platelets stored at room temperature for 5 days, with infection rate of 0.25% </li></ul><ul><li>III. Protozoal </li></ul><ul><li>Trypanosoma cruzi (Chaga’s disease) </li></ul><ul><li>Malaria </li></ul><ul><li>Toxoplasmosis </li></ul><ul><li>Leishmaniasis </li></ul>
  46. 47. Serological Testing for Infectious markers <ul><li>HIV – Ag </li></ul><ul><li>Anti – HIV </li></ul><ul><li>HBsAg </li></ul><ul><li>Anti – HCV </li></ul><ul><li>Test for syphilis </li></ul>
  47. 48. METABOLIC COMPLICATIONS <ul><li>Citrate toxicity </li></ul><ul><li>Citrate (3G/ unit WB) binds Ca 2+ / Mg + </li></ul><ul><li>Metabolized liver, mobilization bone stores </li></ul><ul><li>Hypocalcemia ONLY if > 1 unit/ 5 min or hepatic dysfunction </li></ul><ul><li>Hypotension more likely due to  cardiac output/ perfusion than  calcium (except neonates) </li></ul><ul><li>Worse with hypothermia/ hepatic dysfunction </li></ul>
  48. 49. <ul><li>Hyperkalemia </li></ul><ul><li>After 3 weeks, K + is 25- 30 mmol/l </li></ul><ul><li>Only 8- 15 mmol per unit PRBC/ WB </li></ul><ul><li>Concern with > 1 unit/5 min @ infants </li></ul>
  49. 50. <ul><li>Acidosis </li></ul><ul><li>Acid load after after 3 weeks 30-40 mmol/l (pH 6.6 - 6.9) </li></ul><ul><li>Metabolic acidosis more likely due to decreased perfusion, hepatic impairment, hypothermia </li></ul><ul><li>NaHCO 3 or THAM if base deficit > 7-10 mEq/l </li></ul>
  50. 51. <ul><li>2, 3 DPG </li></ul><ul><li>Depleted within 96 hours of storage </li></ul><ul><li>O 2 Hb DC to left </li></ul><ul><li>Restored within 8- 24 hours of transfusion </li></ul>
  51. 52. E. REFERENCES <ul><li>Practice Guidelines for Blood Component Therapy (ASA Task Force). Anesthesiology 1996; 84: 732-47. </li></ul><ul><li>Safety of the Blood Supply. JAMA 1995; 274:1368--73. </li></ul><ul><li>Infectious Disease Testing for Blood Transfusions (NIH Consensus Conference). JAMA 1995; 274: 1374-9. </li></ul>